MedTrace Logo

Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy

NCT02574962 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2016-07-18

No results posted yet for this study

Summary

The purpose of this pilot study is to assess the safety and efficacy of Acthar® Gel in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients.

Conditions

Interventions

DRUG

H.P. Acthar® Gel

Sponsors & Collaborators

  • Mallinckrodt

    collaborator INDUSTRY

  • Mamatha Pasnoor, MD

    lead OTHER

Principal Investigators

  • Mamatha Pasnoor, MD · University of Kansas Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2018-07-31
Completion
2018-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02574962 on ClinicalTrials.gov